Related Experiment Video

Updated: Jun 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Castration-resistant prostate cancer: current and emerging treatment strategies

Giuseppe Di Lorenzo1, Carlo Buonerba, Riccardo Autorino

  • 1Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, Naples, Italy. giuseppedilorenzoncol@hotmail.com

Drugs
|May 21, 2010
PubMed

Insights

New therapies are emerging for castration-resistant prostate cancer (CRPC), offering hope beyond docetaxel. Sipuleucel-T and cabazitaxel show significant survival benefits, with sipuleucel-T now FDA-approved.

Area of Science:

  • Oncology
  • Urology

Background:

  • Docetaxel was the sole approved treatment for castration-resistant prostate cancer (CRPC).
  • There is an urgent need for novel therapeutic options for CRPC patients.
  • Recent advancements include hormonal, cytotoxic, targeted, and immune therapies.

Purpose of the Study:

  • To review recent therapeutic advancements in castration-resistant prostate cancer.
  • To discuss the impact of new drug development on CRPC treatment.
  • To highlight the role of updated clinical trial guidelines in drug evaluation.

Main Methods:

  • Review of recent clinical trials and pharmaceutical investigations in CRPC.
  • Analysis of data from large phase III trials, including sipuleucel-T and cabazitaxel.
  • Discussion of innovations in study design by the Prostate Cancer Clinical Trials Working Group (PCWG2).

Main Results:

  • Sipuleucel-T and cabazitaxel demonstrated significant prolongation of overall survival in CRPC.
  • Sipuleucel-T received US FDA approval for CRPC treatment.
  • Numerous other pharmaceuticals are under investigation in phase III trials for potential efficacy.

Conclusions:

  • The therapeutic landscape for CRPC is rapidly evolving with new effective agents.
  • Updated clinical trial methodologies enhance the identification of promising CRPC drugs.
  • Future treatments for CRPC are expected to improve patient outcomes significantly.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...